Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Voyant, Allergan Enter Exclusive R&D Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Voyant, Allergan Enter Exclusive R&D Alliance

Aims to identify disease targets for new therapeutics to treat ocular disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Voyant Biotherapeutics, LLC, a company formed out of The John A. Moran Eye Center at the University of Utah’s Center for Translational Medicine (CTM), has signed an exclusive R&D collaboration with Allergan to identify disease-associated pathways and targets for the development of new therapeutics to treat ocular disease. The collaboration will focus on new treatments for age-related macular degeneration (AMD), a leading cause of irreversible vision loss. The agreement provides for a combination of undisclosed upfront, research and milestone payments.
 
“This relationship is special in that it is a true collaboration between CTM, Voyant and Allergan scientists,” said Gregory Hageman, Ph.D., John A. Moran presidential professor, Dept. of Ophthalmology and Visual Sciences, and executive director of Moran’s CTM. “The CTM’s incredibly talented, multidisciplinary research team and its unique cadre of resources have provided a robust understanding of AMD and a solid platform upon which to conduct this collaboration.”
 
“We are extremely excited about the significance of this collaboration,” said Dr. Randall Olson, chief executive officer of the Moran Eye Center. “This collaboration could not have happened without the generous contributions of hundreds of people supporting the CTM in its quest to find new treatments for the prevention and treatment of AMD and other ocular diseases. This collaboration is further testament to the groundbreaking research that is being conducted at the Moran.”
 
“We look forward to a productive collaboration with Voyant to identify and develop novel therapies for retinal disease. This agreement highlights Allergan’s commitment to academic and corporate partnerships to increase long-term innovation,” said Scott Whitcup, chief scientific officer and executive vice president of R&D at Allergan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics